Introduction
============

Pediatric tumors are inherently different from tumors that develop in adults ([@B24]) since they are supposedly derived from defects of cell differentiation and organogenesis ([@B2]). Embryonal tumors are a special class of childhood cancers characterized by a very early-onset exhibiting histological features that resemble developmental stages of the origin organ ([@B24]).

Cancer development involves the accumulation of genetic mutations over an extended period of time ([@B11]); however, this model is not suitable for pediatric cancer, which develops in a short temporal window, usually carrying a low number of somatic mutations ([@B42]; [@B10]). A more comprehensive background takes into account the dysregulation of epigenetic mechanisms ([@B37]), considering the interplay between genetic and epigenetic factors as a key element for tumor development ([@B39]). Among the epigenetic regulators, DNA methylation, which occurs through the addition of a methyl group to a cytosine (5mC) by DNA methyltransferase enzymes (DNMTs) ([@B16]), has been extensively investigated. In tumor cells, well-known DNA methylation disturbances include repression of tumor suppressor genes by promoter hypermethylation, and hypomethylation at repetitive sequences, leading to genomic instability ([@B23]; [@B36]).

Hepatoblastoma is a rare liver embryonal tumor, and the most common form of liver tumor in children ([@B43]; [@B22]), with an incidence of 1-2.4 per million children each year ([@B32]). These tumors carry few genetic alterations, mainly gains of chromosomes 2, 8, 20, and chromosome 18 deletion ([@B40]; [@B30]; [@B35]), and recurrent *CTNNB1* activating mutations; low frequency mutations of other *Wnt* pathway genes, such as *AXIN1, AXIN2, AXIN3* and *APC*, have also been reported ([@B40]; [@B9]; [@B14]). In a recent work from our group ([@B25]), the evaluation of hepatoblastoma methylomes disclosed a genome-wide methylation dysfunction, characterized by hypermethylation at specific CpG islands, in addition to a low-level hypomethylation pattern in non-repetitive intergenic sequences, the later finding corroborated by others ([@B8]).

DNA hydroxymethylation is a kind of DNA modification ([@B28]) originated by 5mC conversion to 5-hydroxymethylcytosine (5hmC), in a process catalyzed by proteins encoded by *TET* genes. The 5hmC is an intermediate residue of the active demethylation process and seems to be related to pluripotency maintenance in stem cells and transcriptional activation ([@B44]; [@B17]).

To elucidate the underlying mechanisms resulting in DNA methylation loss in hepatoblastomas, we evaluated the expression profiles of the *DNMT* and *TET* genes as well as the global level of 5hmC in a hepatoblastomas cohort.

Materials and Methods {#s1}
=====================

Samples
-------

Nineteen hepatoblastoma samples (HBs) and eight paired non-tumoral liver tissue samples were obtained from hepatoblastoma patients submitted to surgical resection in two pediatric cancer institutions (A. C. Camargo Cancer Center and GRAACC, São Paulo, Brazil). This study was carried out in accordance with the recommendations of Research Ethics Committee - A.C. Camargo Cancer Center, Brazil (registration number 1987/14), with written informed consent from all parents/guardian of participants. Clinical features of this HB cohort are described in [Supplementary Table 1](#SM1){ref-type="supplementary-material"}. All patients received pre-surgery chemotherapy according to the SIOPEL protocol^[1](#fn01){ref-type="fn"}^ and COG protocol^[2](#fn02){ref-type="fn"}^.

Methods
-------

### Gene Expression Analysis

Microfluidics-based electrophoresis (Bioanalyzer, Agilent Technologies; CA, United States) was performed to verify quality, and only RNA samples with RNA Integrity Number (RIN) \> 7.0 were used for gene expression analysis. The cDNA was synthesized with the High Capacity RNA-to-cDNA kit (Applied Biosystems, EUA) according to standard procedures. The experiment was designed and interpreted according to recommendations contained in International Guideline MIQE (The Minimum Information for Publication of Quantitative Real-Time PCR Experiments). The suitable housekeeping gene was chosen using the geNorm algorithm ([@B41]) after expression analysis of *ACTB*, *GAPDH*, *B2M* genes and 18S ribosomal RNA (18S rRNA). Data were normalized using the expression values of the housekeeping gene 18S rRNA, and all reactions were performed with three technical replicates. The delta-delta *C*~t~ (ΔΔ*C*~t~) method was used for data analysis ([@B21]). The Kruskal Wallis *post hoc* Dunn test with Bonferroni correction was used for statistical analysis in the GraphPad Prism 7 software.

5-Hydroxymethylcytosine (5hmC) Quantification
---------------------------------------------

Nanodrop (Thermo Fisher Scientific, United States) was used to access quantity and integrity of DNA samples. The 5hmC global level quantification of 18 HBs and eigth paired non-tumoral liver tissue samples was carried out using the MethylFlash Hydroxymethylated DNA 5-hmC Quantification Kit (Epigentek, United States). The values of each sample are given as percentages relative to internal controls of the kit, according to the manufacturer's recommendation. The *t*-test was used for the statistical analysis.

Results
=======

Gene expression analysis of five DNA methylation genes (*DNMT1, DNMT3A, DNMT3B, DNMT3L*, and *UHRF1*) revealed up-regulation of *DNMT3A* (fold-change mean: 7.0; *p*-value: 0.024) and *DNMT1* (fold-change mean: 3.6; *p*-value: 0.012) expression in the group of 19 HBs as compared to eight paired non-tumoral liver tissues, while *DNMT3B* and *DNMT3L* expression values were not significantly altered ([Figure 1](#F1){ref-type="fig"}). Data also showed a very significant increase in *UHRF1* expression in tumor samples (fold-change mean: 20.4; *p*-value: 0.015).

![Expression analysis of DNA methylation genes in hepatoblastomas. *DNMT1, DNMT3A* and *UHRF1* upregulation in 19 tumor samples compared with eight non-tumoral liver samples as evidenced by RT-qPCR. Control Liver: non-tumoral liver tissue samples; HB: hepatoblastoma samples. Endogenous gene: *18S rRNA*. The Kruskal Wallis *post hoc* Dunn test with Bonferroni correction was used for statistical analysis. ^∗^*p*-value \< 0.05, ^∗∗^*p*-value \< 0.01.](fgene-10-00553-g001){#F1}

The hydroxymethylation process was evaluated by assessing the expression level of the three *TET* genes, and all of them were found to be significantly upregulated in hepatoblastomas as compared to non-tumoral liver tissue ([Figure 2A](#F2){ref-type="fig"}): *TET1* (fold-change mean: 21.5; *p*-value: 0.009), *TET2* (fold-change mean: 7.15; *p*-value: 0.009), and *TET3* (fold-change mean: 4.3; *p*-value: 0.024). Given the observed *TET* genes upregulation in HBs, the global content of 5hmC was evaluated in tumors and control hepatic tissues. Regardless of the variability in total 5hmC content seen across HBs, an overall enrichment of approximately 2.5× (*p*-value 4.2e-05; *t*-test) was observed in tumors (mean: 0.33%; SD: 0.15) relative to non-tumoral livers (mean: 0.13%; SD: 0.07) ([Figure 2B](#F2){ref-type="fig"}). Statistical analysis based on the clinical data showed that patients with overall survival ≤ 5 years exhibited a 5hmC content lower than the mean of the tumor group (*p*-value 0.02; Fisher's test) ([Figure 3](#F3){ref-type="fig"}), closer to the level that was detected in the group of non-tumoral liver tissues.

![Analysis of DNA hydroxymethylation in hepatoblastomas. **(A)** Expression analysis of DNA hydroxymethylation genes in hepatoblastomas. Upregulation of three genes of the *TET* family in 19 tumor samples compared with eight non-tumoral liver samples as evidenced by RT-qPCR. Control Liver: non-tumoral liver tissue samples; HB: hepatoblastoma samples. Endogenous gene: *18S rRNA*. The Kruskal Wallis *post hoc* Dunn test with Bonferroni correction was used for statistical analysis. ^∗^*p*-value \< 0.05; ^∗∗^*p*-value \< 0.01. **(B)** 5hmC global level enrichment in hepatoblastoma samples. Violin plots showing the overall level of 5hmC in percentage in hepatoblastomas samples (red) and non-tumoral liver tissues (blue). Hepatoblastoma samples mean: 0.33%, SD: 0.15; non-tumoral liver tissue samples mean: 0.13%; SD: 0.07. The *t*-test was used for the statistical analysis. *p*-value: 4.2e-05.](fgene-10-00553-g002){#F2}

![Decreased overall survival is associated with lower levels of 5hmC. This figure shows the 5hmC global content of 18 tumor samples in the columns and their respective clinical data below. Tumor samples with overall survival ≤ 5 years present reduced 5hmC content, below the mean of the tumor group (0.33% - represented by the dashed line) and close to the level of non-tumoral hepatic tissues (CL). The Fisher's test was used for the statistical analysis. *p*-value 0.02. CL: non-tumoral liver tissue samples; T: hepatoblastoma tumor samples. ^∗^According to the CHIC criteria ([@B26]).](fgene-10-00553-g003){#F3}

Discussion
==========

We previously reported changes in the methylation profile of hepatoblastomas, with global hypomethylation in intergenic non-repetitive sequences, as well as hypermethylation at CpG islands, affecting genes associated with tumor suppression, lipid metabolism, and liver differentiation ([@B25]). Except for the *UHRF1* gene ([@B5]), here we disclosed for the first time dysregulated expression of genes from the DNA methylation machinery that could be related to the detected epigenetic disturbance, such as upregulation of *DNMT3A, DNMT1, UHRF1*, and the *TET* family of genes.

The interaction between UHRF1/DNMT1 plays a pivotal role in the inheritance of DNA methylation patterns, even though the details of this complex network remain under analysis. Thus, *UHRF1* is considered an essential epigenetic regulator for DNA methylation maintenance ([@B6]). It is known that UHRF1/DNMT1 are involved in the maintenance of the hypermethylation of tumor suppressor gene promoters in cancer ([@B1]; [@B3]); in particular, overexpression of *UHRF1* was recently reported to silence specific tumor suppressor genes in hepatoblastomas ([@B5]). Indeed, enhanced *UHRF1* expression was identified in all cancers so far examined ([@B3]). Therefore, it is possible that *DNMT1* and *DNMT3A* upregulation observed in the present study contributes to the hypermethylation at specific CpG islands we previously reported in hepatoblastomas. Nevertheless, it has also been suggested that impaired interaction between UHRF1 and DNMT1 could be the origin of the global hypomethylation in cancer cells ([@B12]; [@B31]). Moreover, a different line of evidence revealed that *UHRF1* overexpression also acts as a negative regulator by degradation of the *de novo* DNA methylation protein, DNMT3A, as an additional mechanism leading to widespread DNA hypomethylation in cancer cells ([@B15]). Complementary to these findings, [@B27] demonstrated in both zebrafish hepatocytes and hepatocellular carcinoma that *UHRF1* overexpression promotes DNMT1 destabilization and de-localization, driving DNA hypomethylation; further, *UHRF1* increased expression was already associated with poor prognosis in hepatocellular carcinoma, contributing to cell proliferation and metastasis ([@B20]). These data further support the hypothesis that disruption of normal cooperation of DNA methylases and *UHRF1* can play a dual role in the patterns of DNA methylation in cancer cells, which mechanisms remain partially elusive. In combination with our results, these evidences suggest that, at least in liver cancer, including hepatoblastomas, the disclosed *UHRF1* overexpression may result in inefficient or impaired DNA methylation process, irrespective of the *DNMTs* expression level, contributing to the global low level hypomethylation pattern in non-repetitive intergenic sequences reported in hepatoblastomas ([@B8]; [@B25]) and hepatocellular carcinoma ([@B38]).

The conversion of methylated cytosine to 5hmC, mediated by *TET* enzymes, is the first step in the DNA demethylation active pathway ([@B44]; [@B17]; [@B33]). In adult cancer, a decrease in *TET* expression was reported to reduce the 5hmC level in solid and hematological tumors ([@B18]; [@B19]; [@B34]; [@B33]). However, the activity of these enzymes in pediatric tumors is poorly explored. Despite the limited size of our cohort, here we showed an increased expression of *TET* genes in hepatoblastomas, suggesting the occurrence of an active demethylation mechanism. Studies with animal models described *TET* overexpression in embryonic development stages repressing differentiation ([@B13]; [@B34]; [@B33]), as well as in cellular reprogramming of IPS cells ([@B4]). Thus, we can speculate that *TET* upregulation in hepatoblastomas indicates the occurrence of a blockage of liver differentiation, which corroborates the long-standing hypothesis of repression of the differentiation pathway of the origin organ leading to embryonal tumors genesis ([@B24]). A functional role for the observed *TET* overexpression was substantiated by the enrichment of the 5hmC content in these tumors, then partially explaining the DNA hypomethylation described in hepatoblastoma, in addition to the possible impaired *de novo* methylation caused by the observed *UHRF1* overexpression. An additional analysis regarding the underlying nature of the DNA sequences with 5hmC enrichment in hepatoblastomas (if intergenic non-repetitive or CpG islands) would add valuable information, and should be made in the future. Remarkably, in hepatocellular carcinoma, a reduced 5hmC content was directly associated with lower overall survival and poor prognosis ([@B19]). Our findings also suggested that lower levels of 5hmC in hepatoblastomas could be associated with decreased overall survival, highlighting the 5hmC content as a potential biomarker of risk for these tumors. However, these preliminary results require further validation in a larger cohort of hepatoblastomas.

This study addressed possible mechanisms leading to the hypomethylation pattern displayed by hepatoblastomas. Our data revealed disturbance in the expression of genes related to the DNA methylation machinery and enrichment of the 5hmC content in hepatoblastomas. As hepatoblastomas exhibit the lowest mutation rate reported so far for pediatric solid tumors ([@B10]), this analysis of genes of the epigenetic machinery provides evidence that epigenetic disruption is probably key for the onset of this liver embryonal tumor, and highlights the 5hmC content as a potential biomarker for poor overall survival.
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